Sign In
Buy AIMT
$34.49
+0 (+0%)
At Close: May 27, 2022
Aimmune Therapeutics (AIMT) Q2 2020 Earnings Call Transcript
07:32am, Friday, 31'st Jul 2020
Before we begin, I would like to remind you that during today's call and Q&A session, we will be making forward-looking statements. Risks and uncertainties that contribute to the uncertain nature of
Aimmune Therapeutics (AIMT) Reports Q2 Loss, Misses Revenue Estimates
10:20pm, Thursday, 30'th Jul 2020
Aimmune Therapeutics (AIMT) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Aimmune Therapeutics, Inc. (AIMT) CEO Jayson Dallas on Q2 2020 Results - Earnings Call Transcript
09:03pm, Thursday, 30'th Jul 2020
Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Q2 2020 Earnings Conference Call July 30, 2020, 16:30 ET Company Participants DeDe Sheel - VP, IR Jayson Dallas - President, CEO & Director Daniel Adelman
Aimmune Therapeutics Announces Second Quarter 2020 Financial Results and Provides Recent Operational Highlights
08:05pm, Thursday, 30'th Jul 2020
Aimmune Therapeutics Announces Second Quarter 2020 Financial Results and Provides Recent Operational Highlights
These Analysts Think Aimmune Therapeutics, Inc.'s (NASDAQ:AIMT) Sales Are Under Threat
10:20am, Thursday, 30'th Jul 2020
One thing we could say about the analysts on Aimmune Therapeutics, Inc. (NASDAQ:AIMT) - they aren't optimistic, having...
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 29)
Abbott Laboratories (NYSE: ABT)
ABIOMED, Inc. (NASDAQ: ABMD)
Adamis Pharmaceuticals Corp (NASDAQ: ADMP)
Annexon...
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Recent Operational Highlights
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, tod
Full Results of Aimmune’s Pivotal Phase 3 European ARTEMIS Trial of PALFORZIA® Published in The Lancet Child & Adolescent Health
12:30pm, Tuesday, 21'st Jul 2020
Full Results of Aimmune’s Pivotal Phase 3 European ARTEMIS Trial of PALFORZIA® Published in The Lancet Child & Adolescent Health
Loss-Making Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Expected To Breakeven
01:33pm, Saturday, 18'th Jul 2020
Aimmune Therapeutics, Inc.'s (NASDAQ:AIMT): Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company...
Benzinga's Top Upgrades, Downgrades For July 13, 2020
01:32pm, Monday, 13'th Jul 2020
Upgrades * For Darden Restaurants Inc (NYSE: DRI), JP Morgan upgraded the stock from Neutral to Overweight. Darden Restaurants earned ($1.24) in the fourth quarter, compared to $1.76 in the year-ago
Aimmune Therapeutics (NASDAQ:AIMT) Coverage Initiated by Analysts at Cowen
07:08am, Monday, 13'th Jul 2020
Research analysts at Cowen assumed coverage on shares of Aimmune Therapeutics (NASDAQ:AIMT) in a research note issued on Monday, Briefing.com Automated Import reports. The brokerage set an “outperfo
10 Best Stocks for 2020: Don't Take Your Seat Belt Off Just Yet
06:34pm, Thursday, 09'th Jul 2020
How will InvestorPlace.com's Best Stocks for 2020 contest end? Your guess is as good as mine, but Q3 will be an interesting one to watch.
Aimmune Appoints Narinder Singh as Executive Vice President of Technical Operations
12:30pm, Monday, 06'th Jul 2020
Aimmune Appoints Narinder Singh as Executive Vice President of Technical Operations
Aimmune Appoints Narinder Singh as Executive Vice President of Technical Operations
12:00am, Monday, 06'th Jul 2020
Aimmune Appoints Narinder Singh as Executive Vice President of Technical Operations
